InvestorsHub Logo
Post# of 252496
Next 10
Followers 832
Posts 119982
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 243852

Monday, 04/03/2023 10:19:52 AM

Monday, April 03, 2023 10:19:52 AM

Post# of 252496
PRDS fails phase-2 COVID trial—terminates program:

https://finance.yahoo.com/news/pardes-biosciences-announces-top-line-120000532.html

Pomotrelvir (a/k/a PBI-0450) did not achieve the primary endpoint as measured by proportion of participants below the limit of detection for infectious SARS-CoV-2 on day 3 by infectious virus assay (IVA) with 70% reaching undetectable levels in the pomotrelvir treated group versus 63% in the placebo group (p=0.57).

Pomotrelvir did not demonstrate meaningful improvement over placebo in reduction from baseline of SARS-CoV-2 infectious virus titer by IVA or in the reduction from baseline or proportion achieving undetectable viral load (RNA) by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) measured from mid-turbinate swabs.

…Based on these results, the Company will suspend further clinical development of pomotrelvir and the Company’s Board of Directors has initiated a review of a range of strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, or other transaction.

Even if Pomotrelvir had worked, the dosing schedule of 1400mg/day with food (#msg-169951898) was far from ideal.

PRDS had $172M of cash at 3/31/23, so it should be an attractive reverse-merger partner.

p.s. The stock is not down today because it was already trading at only 35% of cash value.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.